Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 2
1986 1
1988 1
1993 1
1994 1
1997 2
1998 1
1999 3
2000 1
2001 2
2005 1
2007 3
2008 1
2009 1
2010 2
2011 1
2012 2
2014 1
2016 1
2018 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
[Acne vulgaris].
Rossen MH, Roed-Petersen J. Rossen MH, et al. Ugeskr Laeger. 1993 Mar 15;155(11):775-8. Ugeskr Laeger. 1993. PMID: 8460427 Review. Danish.
[Acute pancreatitis].
Rossen M, Baden H. Rossen M, et al. Ugeskr Laeger. 1982 Jun 7;144(23):1681-3. Ugeskr Laeger. 1982. PMID: 7135576 Danish. No abstract available.
A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys.
Lauritzen B, Bjelke M, Björkdahl O, Bloem E, Keane K, Kjalke M, Rossen M, Lippert SL, Weldingh KN, Skydsgaard M, Kjellev S. Lauritzen B, et al. Among authors: rossen m. J Thromb Haemost. 2022 Jun;20(6):1312-1324. doi: 10.1111/jth.15682. Epub 2022 Mar 6. J Thromb Haemost. 2022. PMID: 35191180 Free PMC article.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
31 results